Results 51 to 60 of about 4,076 (204)

An epilepsy-associated SV2A mutation disrupts Synaptotagmin-1 expression and activity-dependent trafficking [PDF]

, 2020
The epilepsy-linked gene , has a number of potential roles in the synaptic vesicle (SV) life cycle. However, how loss of SV2A function translates into presynaptic dysfunction and ultimately seizure activity is still undetermined.
Harper, Callista B., Low, Darryl, Cousin, Michael; id_orcid, Small, Christopher, Smillie, Karen, Martínez-Mármol, Ramón, Meunier, Frederic A, Smillie, Karen J., Cousin, Michael A., Harper, Callista, Meunier, Frédéric A., Low, Darryl W., Davenport, Elizabeth C., Davenport, Elizabeth; id_orcid   +13 more
core   +1 more source

Dynamic regional divergence of SV2A expression in a mouse model of primary tauopathy: A longitudinal multi-tracer PET study

NeuroImage
In tauopathies, tau accumulation and neuroinflammation are associated with progressive synaptic and network alterations that contribute to neurodegeneration.
Yunlei Li, Artem Zatcepin, Giovanna Palumbo, Rosel Oos, Karin Wind-Mark, Simon Lindner, Franz-Josef Gildehaus, Johannes Gnörich, Rudolf A Werner, Matthias Brendel, Lea H Kunze   +10 more
doaj   +1 more source

Synaptic density in aging mice measured by [18F]SynVesT-1 PET

NeuroImage, 2023
Synaptic alterations in certain brain structures are related to cognitive decline in neurodegeneration and in aging. Synaptic loss in many neurodegenerative diseases can be visualized by positron emission tomography (PET) imaging of synaptic vesicle ...
Mengfei Xiong, Sahar Roshanbin, Dag Sehlin, Hanne D. Hansen, Gitte M. Knudsen, Johanna Rokka, Jonas Eriksson, Stina Syvänen   +7 more
doaj   +1 more source

Advancing Pregnancy and Pediatric Science through the NIH Transporter Elucidation Network

Clinical Pharmacology &Therapeutics, EarlyView.
Human gestation is characterized by dynamic changes in maternal physiology and maturation of tissue functions before and after birth. The fetus and neonate are highly dependent upon transfer of maternal nutrients via the placenta and lactating mammary gland, which frequently involve selective membrane transporter proteins.
Joanne Wang, Jashvant D Unadkat, Samuel LM Arnold, John K Fallon, Pouria Fattahi, Dan Dongeun Huh, Nicholas Ieronimakis, Edward J Kelly, Svetlana Lutsenko, Robert M Stroud, Jacqueline B Tiley, Jia Yang, Xujia Zhou, Hao Zhu, Rajini Rao, Kathleen M Giacomini, Lauren M Aleksunes   +16 more
wiley   +1 more source

Image_4_Connectivity Mapping Using a Novel sv2a Loss-of-Function Zebrafish Epilepsy Model as a Powerful Strategy for Anti-epileptic Drug Discovery.PDF

, 2022
Synaptic vesicle glycoprotein 2A (SV2A) regulates action potential-dependent neurotransmitter release and is commonly known as the primary binding site of an approved anti-epileptic drug, levetiracetam.
Lise Heylen (11561266), Patrice Godard (3476651), Yifan Zhang (119570), Michèle Partoens (12620839), Aleksandra Siekierska (11561278), Rafal M. Kaminski (12620842), Peter A. M. de Witte (11561275), James D. Mills (9418733), Michel Gillard (261248)   +8 more
core   +1 more source

Potential of [11C]UCB-J as a PET tracer for islets of Langerhans

Scientific Reports, 2021
Biomarkers for the measurement of islets of Langerhans could help elucidate the etiology of diabetes. Synaptic vesicle glycoprotein 2 A (SV2A) is a potential marker reported to be localized in the endocrine pancreas.
Emmi Puuvuori, Johanna Rokka, Per-Ola Carlsson, Zhanchun Li, Jonas Eriksson, Olof Eriksson   +5 more
doaj   +1 more source

Efficacy of fenfluramine in a pediatric epilepsy patient with a pathogenic SV2A variant: A case report

Epileptic Disorders, EarlyView.
Abstract Pathogenic SV2A gene variants have been reported as causes of epilepsy and are often associated with drug resistance and susceptibility to fever‐related seizures. No highly effective treatments have been established for this condition. We report a female patient with a family history of epilepsy who developed generalized seizures associated ...
Takayuki Mori, Hiroshi Terashima, Yu kakimoto, Mitsuhiro Kato, Shumpei Uchino   +4 more
wiley   +1 more source

Preclinical radiation dosimetry for the novel SV2A radiotracer [18F]UCB-H [PDF]

EJNMMI Research, 2013
Abstract Background [18F]UCB-H was developed as a novel radiotracer with a high affinity for synaptic vesicle protein 2A, the binding site for the antiepileptic levetiracetam. The objectives of this study were to evaluate the radiation dosimetry of [18F]UCB-H in a preclinical trial and to determine the maximum ...
Bretin, Florian, Warnock, Geoffrey, Bahri, Mohamed Ali, Aerts, Joël, Mestdagh, Nathalie, Buchanan, Tim, Valade, Anne, Mievis, Frédéric, Giacomelli, Fabrice, Lemaire, Christian, Luxen, André, Salmon, Eric, Seret, Alain, Plenevaux, Alain   +13 more
openaire   +2 more sources

SV2A is expressed in subpopulations of mouse and human synapses

Synapse pathology is a feature of most brain diseases and there is a pressing need to monitor the onset and progression of this pathology using brain imaging in living patients.
Tavares, Adriana, Grant, Seth GN, Qiu, Zhen, Smith, Colin, Notman, Beverly, Wong, Theresa   +5 more
core   +2 more sources

Loss of the SV2-like protein SVOP produces no apparent deficits in laboratory mice. [PDF]

PLoS ONE, 2013
Neurons express two families of transporter-like proteins - Synaptic Vesicle protein 2 (SV2A, B, and C) and SV2-related proteins (SVOP and SVOPL). Both families share structural similarity with the Major Facilitator (MF) family of transporters.
Jia Yao, Horacio O de la Iglesia, Sandra M Bajjalieh   +2 more
doaj   +1 more source